Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults

AIDS

Volumn 21, Issue 14, 2007, Pages 1849-1854

  Anderson, Peter L ^a   Zheng, Jia Hua ^a   King, Tracy ^a   Bushman, Lane R ^a   Predhomme, Julie ^a   Meditz, Amie ^a   Gerber, John ^a   Fletcher, Courtney V ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE PLUS ZIDOVUDINE; PHOSPHATE; TRIPHOSPHATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CYTIDINE TRIPHOSPHATE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV SERONEGATIVITY; HUMANS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHOSPHORYLATION; REVERSE TRANSCRIPTASE INHIBITORS; THYMINE NUCLEOTIDES; ZIDOVUDINE;

EID: 34548219647     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282741feb     Document Type: Article

References (22)

1. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22:685-708.
2. Hoggard PG, Back DJ. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules. Curr Opin Infect Dis 2002; 15:3-8.
3. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 2004; 38:743-753.
4. Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD. Transport of antiviral 3′-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol 2001; 18:161-167.
5. Yao SY, Ng AM, Loewen SK, Cass CE, Baldwin SA, Young JD. An ancient prevertebrate NaR-nucleoside cotransporter (hfCNT) from the Pacific hagfish (Eptatretus stouti) 10.1152/ajpcell.00587.2001. Am J Physiol Cell Physiol 2002; 283:C155-C168.
6. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999; 5:1048-1051.
7. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986; 83:8333-8337.
8. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276:40847-40857.
9. Barry M, Wild M, Veal G, Back D, Breckenridge A, Fox R, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994; 8:F1-5.
10. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17:2159-2168.
11. Division of AIDS table for grading severity of adult adverse experiences. National Institutes of Allergy and Infectious Disease. December 2004.
12. King T, Bushman L, Anderson PL, Delahunty T, Ray M, Fletcher CV. Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 831 (1-2):248-257.
13. Yuen GJ, Lou Y, Bumgarner NF, Bishop JP, Smith GA, Otto VR, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother 2004; 48:176-182.
14. Wattanagoon Y, Na Bangchang K, Hoggard PG, Khoo SH, Gibbons SE, Phiboonbhanakit D, et al. Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive Thai patients and healthy volunteers. Antimicrob Agents Chemother 2000; 44:1986-1989.
15. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993; 91:2326-2333.
16. Gao WY, Agbaria R, Driscoll JS, Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 20,30-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994; 269:12633-12638.
17. Turriziani O, Butera O, Gianotti N, Parisi SG, Mazzi R, Girardi E, et al. Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. AIDS 2005; 19:473-479.
18. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921-1930.
19. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine and tenofovir DF. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 51].
20. Anderson PL, Kakuda TN. Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother 2006; 58:220-221.
21. Kuritzkes DR. Less than the sum of its parts: failure of a tenofovir-abacavir-lamivudine triple-nucleoside regimen. J Infect Dis 2005; 192:1867-1868.
22. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA III, et al., and the AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection 10.1056/NEJMoa031772. N Engl J Med 2004; 350:1850-1861.